Production of tumor necrosis factor-alpha by [actual symbol not reproducible] T cells in Kawasaki disease p. 206

Complement depletion inhibits Lactobacillus casei-inducible coronary arteritis in a murine model p. 213

Soluble cell adhesion molecules and von Willebrand factor in Kawasaki disease p. 220

Chemokine gene expression in Kawasaki disease p. 226

Persistent immune abnormalities in Kawasaki disease after IVIG therapy p. 232

Immunoregulation and pentoxifylline therapy during acute Kawasaki disease p. 237

A clinical investigation of Kawasaki disease documented with Yersinia pseudotuberculosis infection ANCA are not increased in Kawasaki disease p. 241 p. 248

Human IVIG inhibits Lactobacillus casei-inducible coronary arteritis in a murine model Human IVIG inhibits Lactobacillus casei-inducible coronary arteritis in a murine model Urinary excretion of prostacyclin in Kawasaki disease before and after gammaglobulin Human IVIG inhibits Lactobacillus casei-inducible coronary arteritis in a murine model Urinary excretion of prostacyclin in Kawasaki disease before and after gammaglobulin

Increased serum laminin in patients with Kawasaki disease p. 261

Immunohistochemical demonstration of adhesion molecules in patients with Kawasaki disease p. 265

Increase of tissue factor and haemostatic molecular markers in Kawasaki disease p. 269

High urinary nitrate and nitrite excretion in Kawasaki syndrome p. 272

Nitric oxide production and nitric oxide synthase activity in Kawasaki disease p. 277

Epitope mapping of mycobacterial HSP65 and P1 protein using sera of Kawasaki disease. p. 281

Analysis of Candida albicans extract causing angitis in mice as an animal model of Kawasaki disease p. 284

Comparative safety and efficacy of two immune globulin products in Kawasaki disease p. 291

Intravenous gammaglobulin treatment in Kawasaki syndrome: are all brands equal? p. 296

IVGG treatment of Kawasaki disease: are all brands equal? p. 301

Does treatment of Kawasaki disease within the first 7 days of illness improve the long-term outcome compared to later (8-10th day) treatment? p. 305

How does the early start of gammaglobulin therapy influence the prognosis of Kawasaki syndrome? p. 310

Kawasaki disease in infants less than one year of age p. 315

Intravenous gammaglobulin treatment of Kawasaki disease in Japan p. 321

Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease p. 328

Selective gammaglobulin treatment in Kawasaki disease: single 2 g/kg or 400 mg/kg/day for 5 days? p. 332

A predictive instrument for coronary aneurysms p. 339

Gammaglobulin therapy of Kawasaki disease p. 343

The relationships between gammaglobulin administration and severity change in Kawasaki syndrome p. 348

Intravenous gammaglobulin and outcome of coronary arteries in Kawasaki disease p. 354

Outcome of children with Kawasaki disease p. 359
Preventive effects of ulinastatin for coronary artery aneurysm formation in Kawasaki disease p. 364
Selective gammaglobulin therapy in Kawasaki disease p. 372
Risk factors for coronary lesions in acute Kawasaki disease p. 377
Clinical spectrum of Kawasaki disease in infants younger than 3 months of age p. 381
Plasma endothelin-1 level in acute phase of Kawasaki disease p. 391
Histopathological analysis of the myocardium in Kawasaki disease: comparison with the angiographic findings? p. 396
Electron microscopic findings of myocardial biopsy correlated with perfusion scan and coronary angiography in chronic Kawasaki syndrome myocellular ischemia possibly due to microvasculopathy p. 401
A Study of the measurement of serum immunosuppressive acidic protein in patients with Kawasaki disease p. 411
Abdominal aneurysm in Kawasaki disease: a case report p. 416
Liver dysfunction in acute phase Kawasaki disease p. 422
Organ impairment in acute phase Kawasaki disease p. 427
Degenerative changes in neutrophils in Kawasaki disease p. 432
Reye syndrome following Kawasaki syndrome confirmed by liver histopathology p. 436
How to evaluate myocardial ischemia in Kawasaki disease p. 447
Observation of coronary arterial lesion due to Kawasaki disease by intravascular ultrasound p. 451
Intravascular ultrasound study in Kawasaki disease: assessment of coronary and systemic arterial pathology, and application for coronary intervention p. 460
Combination of dobutamine stress and myocardial contrast echocardiography Kawasaki disease p. 466
Pharmacologic stress myocardial perfusion imaging for the detection of coronary stenotic lesions due to Kawasaki disease: comparison of dobutamine and adenosine triphosphate disodium stress p. 472
Aortic wall abnormalities in patients after Kawasaki disease: evaluation using ultrafast computed tomography p. 479
Myocardial ischemia in Kawasaki disease; evaluation by dipyridamole [superscript 201]thallium myocardial imaging using segmental analysis p. 485
Wall abnormality of apparently normal coronary artery after Kawasaki disease p. 489
Usefulness of UFCT to detect myocardial damage due to stenotic lesion p. 494
Studies on myocardial imaging by [superscript 123]I-MIBG in patients with Kawasaki disease p. 498
Percutaneous transluminal coronary angioplasty in Kawasaki disease: five case reports and literature review p. 507
Development of the coronary collaterals in children with the obstructive coronary lesion p. 513
Long-term therapeutic strategies in patients with Kawasaki disease who suffered from old myocardial infarction p. 517
The worldwide experience with cardiac transplantation for Kawasaki disease p. 522
Estimation of blood flow in coronary aneurysm using multiplanar cine magnetic resonance imaging p. 527
Coronary angiography and segmented cine MRI in a single breath-hold to detect the coronary arterial aneurysm following Kawasaki disease p. 531